WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Eli Lilly and Company

LillyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

www.lilly.com

Eli Lilly and Company RSS Channel

Filters
List of articles in category Eli Lilly and Company
Title Published Date
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial 22 January 2021
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 07 December 2020
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19 24 November 2020
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 13 November 2020
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine 04 November 2020
Lilly initiates Phase 3 trial of LY-CoV555 for prevention of COVID-19 at long-term care facilities in partnership with the National Institute of Allergy and Infectious Diseases (NIAID) 12 August 2020
Lilly begins world's first study of a potential COVID-19 antibody treatment in humans 26 June 2020
Lilly opens Phase 3 clinical trial in RET-mutant medullary thyroid cancer 03 January 2020
Lilly, Evidation Health and Apple study shows personal digital devices may help in the identification of mild cognitive impairment and mild Alzheimer's disease dementia 09 August 2019
Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgalityâ„¢ (galcanezumab-gnlm) for prevention of episodic cluster headache 15 November 2018
Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting 20 April 2017
Lilly and CoLucid Pharmaceuticals announce agreement for Lilly to acquire CoLucid 20 January 2017
Lilly announces top-line results of solanezumab phase 3 clinical trial 23 November 2016
Lilly Diabetes launches new Disney book for families affected by type 1 diabetes 24 September 2015
Results from the largest known cholesterol survey conducted in the U.S. 05 November 2012
Boehringer Ingelheim and Lilly introduce the My Well Planner lifestyle improvement program 13 September 2012
Lilly Diabetes launches mobile application for whose who support people with type 1 diabetes 04 September 2012
Lilly reports second-quarter 2012 results 25 July 2012
Lilly expands strategic partnership with Chinese manufacturer Novast 12 June 2012
Lilly Introduces Global 'Innovation Starts Here' Initiative to Foster Innovation and Quality Science 04 March 2012
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
  • AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX
  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

Research & Development

  • New evidence COVID-19 antibodies, vaccines less effective against variants
  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Eli Lilly and Company
  4. Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.